Grace Therapeutics grants director 12,200 options

A Grace Therapeutics director received a stock option grant for 12,200 shares at a $2.13 exercise price, vesting over one year.

Rhea-AI Filing Summary

Grace Therapeutics, Inc. (GRCE) reported that director Kottayil George received a stock option grant covering 12,200 shares of common stock on September 17, 2026 at an exercise price of $2.13 per share. The option expires on September 16, 2036.

According to the vesting terms, 50% of the option vests on the grant date and the remaining 50% vests in substantially equal monthly installments over a 12‑month period, subject to his continuous service on each vesting date. No Rule 10b5‑1 trading plan is reported for this award.

Insider Trade Summary

Grant/Award: 12,200 shares

Grant/Award 1 txn

Insider Kottayil George

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	12,200	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 12,200 contracts (Direct)

Footnotes (1)

1. F1. 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date.

Key Figures

Stock options granted: 12,200 options Exercise price: $2.13 per share Vesting at grant: 50% of options +3 more

6 metrics

Stock options granted 12,200 options Stock option award to director Kottayil George on September 17, 2026

Exercise price $2.13 per share Exercise price of stock options granted on September 17, 2026

Vesting at grant 50% of options Portion of the 12,200 options vesting immediately on the grant date

Remaining vesting period 12 months Remaining 50% vests in substantially equal monthly installments over 12 months

Options held after transaction 12,200 options Total stock options held directly by Kottayil George following the award

Option expiration date September 16, 2036 Expiration date of the 12,200 stock options granted

Key Terms

Stock Option, vesting, continuous service

3 terms

Stock Option financial

"50% of this option vests on the date of grant and the remaining 50% vests"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vesting financial

"50% of this option vests on the date of grant and the remaining 50% vests"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"subject to the Reporting Person's continuous service as of each vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GRCE report for director Kottayil George?

Grace Therapeutics reported that director Kottayil George received a stock option grant for 12,200 shares of common stock on September 17, 2026, with an exercise price of $2.13 per share and an expiration date of September 16, 2036.

What is the exercise price of the new stock options reported by GRCE?

The stock options granted to director Kottayil George have an exercise price of $2.13 per share. The options relate to 12,200 shares of Grace Therapeutics common stock and were granted on September 17, 2026.

How do the GRCE stock options granted to Kottayil George vest?

The options vest as follows: 50% vests on the grant date, and the remaining 50% vests in substantially equal monthly installments over a 12‑month period, subject to Kottayil George’s continuous service on each applicable vesting date.

When do the newly granted GRCE stock options expire?

The stock options granted to director Kottayil George expire on September 16, 2036. After that date, any unexercised portion of the 12,200‑share option will no longer be exercisable.

Were the GRCE stock option grants made under a Rule 10b5-1 trading plan?

No. The filing indicates that the Rule 10b5‑1 plan checkbox is not marked, so these reported stock option grants to director Kottayil George were not affirmed as being made under a Rule 10b5‑1 trading plan.

How many GRCE options does Kottayil George hold after this grant?

After the reported grant, director Kottayil George holds 12,200 stock options relating to Grace Therapeutics common stock, all from this single award reported in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/21/2026 - 04:13 PM Accepted by SEC EDGAR 09/21/2026 - 04:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kottayil George

(Last) (First) (Middle)

C/O GRACE THERAPEUTICS, INC.

103 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Grace Therapeutics, Inc. [ GRCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.13	09/17/2026		A		12,200		(1)	09/16/2036	Common Stock	12,200	$0	12,200	D

Explanation of Responses:

1. 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date.

	/s/ Robert DelAversano as attorney-in-fact for George Kottayil	09/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)